BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26813866)

  • 1. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
    Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
    Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
    Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
    Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.
    Ungprasert P; Cheungpasitporn W; Srivali N; Kittanamongkolchai W; Bischof EF
    Am J Emerg Med; 2013 Apr; 31(4):756.e1-2. PubMed ID: 23399342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
    Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
    Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.
    Bink KF
    Clin J Oncol Nurs; 2015 Oct; 19(5):E108-14. PubMed ID: 26414586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic anxiety in a woman with breast cancer receiving denosumab.
    Lin KF; Chen KH; Huang WL
    Gen Hosp Psychiatry; 2015; 37(2):192.e7-8. PubMed ID: 25772947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study.
    Nakamura K; Kaya M; Yanagisawa Y; Yamamoto K; Takayashiki N; Ukita H; Nagura M; Sugiue K; Kitajima M; Hirano K; Ishida H; Onoda C; Kobayashi Y; Nakatani E; Odagiri K; Suzuki T
    BMC Cancer; 2024 Feb; 24(1):218. PubMed ID: 38360579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
    J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of skeletal related events in patients with bone metastases from solid tumours].
    Kamby C; Tarp S; Mellemgaard A; Christensen R; Cold S; Eiken P; Jakobsen EH; Langkilde NC; Langkjer ST; Laursen T; Ottesen SS; Pedersen AG; Stenbygaard LE; Vestlev PM
    Ugeskr Laeger; 2014 Feb; 176(8A):V08130525. PubMed ID: 25350304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
    Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
    Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
    Yerram P; Kansagra S; Abdelghany O
    J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.